{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:54:18Z","timestamp":1791258858262,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jval.2026.05.005","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:52:51Z","timestamp":1780617171000},"page":"1805-1813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating Treatment Sequences in Major Depressive Disorder Using an Open-Source Health Economic Model Based on Stakeholder and Patient Engagement"],"prefix":"10.1016","volume":"29","author":[{"given":"Alice Kate","family":"Cummings Joyner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Yuan Michelle","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larragem","family":"Parsley-Raines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Bright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jval.2026.05.005_bib1","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","article-title":"Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States","volume":"75","author":"Hasin","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.jval.2026.05.005_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/a0038550","article-title":"A brief history of the development of antidepressant drugs: from monoamines to glutamate","volume":"23","author":"Hillhouse","year":"2015","journal-title":"Exp Clin Psychopharmacol"},{"issue":"10440","key":"10.1016\/j.jval.2026.05.005_bib3","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","author":"Ferrari","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jval.2026.05.005_bib4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/10673229.2011.614099","article-title":"Quality of life: the ultimate outcome measure of interventions in major depressive disorder","volume":"19","author":"IsHak","year":"2011","journal-title":"Harv Rev Psychiatry"},{"issue":"6","key":"10.1016\/j.jval.2026.05.005_bib5","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40273-021-01019-4","article-title":"The economic burden of adults with major depressive disorder in the United States (2010 and 2018)","volume":"39","author":"Greenberg","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"9690","key":"10.1016\/j.jval.2026.05.005_bib6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(09)60879-5","article-title":"Clinical diagnosis of depression in primary care: a meta-analysis","volume":"374","author":"Mitchell","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jval.2026.05.005_bib7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"D study team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.jval.2026.05.005_bib8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11920-007-0061-3","article-title":"The STAR. The STAR\u2217D project results: a comprehensive review of findings","volume":"9","author":"Warden","year":"2007","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.jval.2026.05.005_bib9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2147\/NDT.S198774","article-title":"Management of treatment-resistant depression: challenges and strategies","volume":"16","author":"Voineskos","year":"2020","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"10.1016\/j.jval.2026.05.005_bib10","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"issue":"2","key":"10.1016\/j.jval.2026.05.005_bib11","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.20m13699","article-title":"The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States","volume":"82","author":"Zhdanava","year":"2021","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.jval.2026.05.005_bib12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40271-022-00596-6","article-title":"Preferences for treatments for major depressive disorder: formative qualitative research using the patient experience","volume":"16","author":"dosReis","year":"2023","journal-title":"Patient"},{"issue":"3","key":"10.1016\/j.jval.2026.05.005_bib13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jval.2024.05.017","article-title":"Patient-informed value elements in cost-effectiveness analyses of major depressive disorder treatment: a literature review and synthesis","volume":"28","author":"Slejko","year":"2025","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2026.05.005_bib14","first-page":"614","article-title":"Real-world treatment modalities, health care resource utilization, and costs among commercially insured patients with newly diagnosed major depressive disorder in the United States","volume":"29","author":"Pizzicato","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"10.1016\/j.jval.2026.05.005_bib15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/13651501.2020.1779308","article-title":"Relapse prevention in recurrent major depressive disorder. A comparison of different treatment options based on clinical experience and a critical review of the literature","volume":"24","author":"Cosci","year":"2020","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"8","key":"10.1016\/j.jval.2026.05.005_bib16","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3390\/jpm11080776","article-title":"Patient-centered care for patients with depression or anxiety disorder: an integrative review","volume":"11","author":"Pinho","year":"2021","journal-title":"J Pers Med"},{"issue":"2","key":"10.1016\/j.jval.2026.05.005_bib17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1192\/bjp.2021.121","article-title":"Appraisal of patient-level health economic models of severe mental illness: systematic review","volume":"220","author":"Altunkaya","year":"2022","journal-title":"Br J Psychiatry"},{"issue":"6","key":"10.1016\/j.jval.2026.05.005_bib18","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s40273-021-01036-3","article-title":"Putting stakeholder engagement at the center of health economic modeling for health technology assessment in The United States","volume":"39","author":"Xie","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"10.1016\/j.jval.2026.05.005_bib19","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR\u2217D Report","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"8","key":"10.1016\/j.jval.2026.05.005_bib20","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40263-015-0267-6","article-title":"Network meta-analysis and cost-effectiveness analysis of new generation antidepressants","volume":"29","author":"Khoo","year":"2015","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.jval.2026.05.005_bib21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00213-007-0975-9","article-title":"Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis","volume":"196","author":"Weinmann","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"10.1016\/j.jval.2026.05.005_bib22","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40273-014-0138-x","article-title":"Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium","volume":"32","author":"Annemans","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.jval.2026.05.005_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2011.09.011","article-title":"Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder","volume":"15","author":"Nordstr\u00f6m","year":"2012","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jval.2026.05.005_bib24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00004850-200609000-00008","article-title":"Escitalopram versus venlafaxine XR in the treatment of depression","volume":"21","author":"Montgomery","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"issue":"14","key":"10.1016\/j.jval.2026.05.005_bib25","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1017\/S0033291715000951","article-title":"Modelling the cost-effectiveness of pharmacotherapy compared with cognitive-behavioural therapy and combination therapy for the treatment of moderate to severe depression in the UK","volume":"45","author":"Koeser","year":"2015","journal-title":"Psychol Med"},{"issue":"11","key":"10.1016\/j.jval.2026.05.005_bib26","doi-asserted-by":"crossref","first-page":"785","DOI":"10.7326\/M18-1480","article-title":"The cost-effectiveness of cognitive behavioral therapy versus second-generation antidepressants for initial treatment of major depressive disorder in the United States: a decision analytic model","volume":"171","author":"Ross","year":"2019","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.jval.2026.05.005_bib27","doi-asserted-by":"crossref","first-page":"331","DOI":"10.7326\/M15-1813","article-title":"Comparative benefits and harms of antidepressant, psychological, complementary, and exercise treatments for major depression: an evidence report for a clinical practice guideline from the American College of Physicians","volume":"164","author":"Gartlehner","year":"2016","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.jval.2026.05.005_bib28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/wps.20701","article-title":"A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression","volume":"19","author":"Cuijpers","year":"2020","journal-title":"World Psychiatry"},{"issue":"2","key":"10.1016\/j.jval.2026.05.005_bib29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/jama.2017.8036","article-title":"Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the VAST-D randomized clinical trial","volume":"318","author":"Mohamed","year":"2017","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jval.2026.05.005_bib30","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/j.jval.2023.03.2335","article-title":"CO200 early remission is associated with lower risk of relapse: analysis of major depressive disorder using STAR\u2217D","volume":"26","author":"Chitnis","year":"2023","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.jval.2026.05.005_bib31","first-page":"1","article-title":"National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics, national vital statistics system","volume":"72","author":"Arias","year":"2023","journal-title":"Natl Vital Stat Rep"},{"issue":"1","key":"10.1016\/j.jval.2026.05.005_bib32","doi-asserted-by":"crossref","DOI":"10.1192\/j.eurpsy.2021.2229","article-title":"Excess mortality in depressive and anxiety disorders: the Lifelines Cohort Study","volume":"64","author":"Oude Voshaar","year":"2021","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.jval.2026.05.005_bib33","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jad.2018.06.030","article-title":"Mortality in treatment-resistant unipolar depression: a register-based cohort study in Sweden","volume":"238","author":"Reutfors","year":"2018","journal-title":"J Affect Disord"},{"issue":"1","key":"10.1016\/j.jval.2026.05.005_bib34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1477-7525-2-20","article-title":"Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder","volume":"2","author":"Sapin","year":"2004","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"10.1016\/j.jval.2026.05.005_bib35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0163-8343(00)00072-4","article-title":"Recovery from depression, work productivity, and health care costs among primary care patients","volume":"22","author":"Simon","year":"2000","journal-title":"Gen Hosp Psychiatry"},{"issue":"12","key":"10.1016\/j.jval.2026.05.005_bib36","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3390\/brainsci10120962","article-title":"Treatment-resistant depression in a real-world setting: first interim analysis of characteristics, healthcare resource use, and utility values of the FondaMental cohort","volume":"10","author":"Yrondi","year":"2020","journal-title":"Brain Sci"},{"issue":"2","key":"10.1016\/j.jval.2026.05.005_bib37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4088\/JCP.17m11725","article-title":"Direct and indirect cost burden and change of employment status in treatment-resistant depression: a matched-cohort study using a US commercial claims database","volume":"79","author":"Amos","year":"2018","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.jval.2026.05.005_bib38","first-page":"226","article-title":"Prospective service use and health care costs of Medicaid beneficiaries with treatment-resistant depression","volume":"24","author":"Olfson","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"issue":"13","key":"10.1016\/j.jval.2026.05.005_bib39","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00023210-200418130-00006","article-title":"A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions","volume":"18","author":"Sullivan","year":"2004","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.jval.2026.05.005_bib40","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12888-016-1173-2","article-title":"Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis","volume":"17","author":"Jakobsen","year":"2017","journal-title":"BMC Psychiatry"},{"issue":"3","key":"10.1016\/j.jval.2026.05.005_bib41","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/gps.5440","article-title":"Adverse events of repetitive transcranial magnetic stimulation in older adults with depression, a systematic review of the literature","volume":"36","author":"Overvliet","year":"2021","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.jval.2026.05.005_bib43","series-title":"Consumer Price Index for All Urban Consumers: medical care (CUUR0000SAM)","year":"2024"},{"issue":"Suppl 10","key":"10.1016\/j.jval.2026.05.005_bib44","first-page":"9","article-title":"American Psychiatric Association practice guidelines for the treatment of patients with major depressive disorder","volume":"167","author":"Gelenberg","year":"2010","journal-title":"Am J Psychiatry"},{"issue":"10","key":"10.1016\/j.jval.2026.05.005_bib45","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.jval.2026.05.005_bib46","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1017\/S0033291711002303","article-title":"Five-year outcome of major depressive disorder in primary health care","volume":"44","author":"Riihim\u00e4ki","year":"2014","journal-title":"Psychol Med"},{"issue":"6 Suppl A","key":"10.1016\/j.jval.2026.05.005_bib47","first-page":"8","article-title":"A budget-impact and cost-effectiveness model for second-line treatment of major depression","volume":"13","author":"Malone","year":"2007","journal-title":"J Manag Care Pharm"},{"issue":"3","key":"10.1016\/j.jval.2026.05.005_bib48","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/0272989X18754513","article-title":"Microsimulation modeling for health decision sciences using R: a tutorial","volume":"38","author":"Krijkamp","year":"2018","journal-title":"Med Decis Mak"},{"issue":"5","key":"10.1016\/j.jval.2026.05.005_bib49","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jval.2019.01.003","article-title":"R you still using excel? The advantages of modern software tools for health technology assessment","volume":"22","author":"Incerti","year":"2019","journal-title":"Value Health"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526024800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526024800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:45:11Z","timestamp":1791258311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301526024800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1098301526024800"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.05.005","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating Treatment Sequences in Major Depressive Disorder Using an Open-Source Health Economic Model Based on Stakeholder and Patient Engagement","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}